IL-8 and VEGFR-2 polymorphisms modulate long-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration

Stefano Lazzeri, Paola Orlandi, Paolo Piaggi, Maria S ole Sartini, Giamberto Casini, Gianluca Guidi, Michele Figus, Anna Fioravanti, Teresa Di Desidero, Guido Ripandelli, Mariacristina Parravano, Monica Varano, Marco Nardi, Guido Bocci

Research output: Contribution to journalArticlepeer-review

Abstract

AIM: To investigate possible associations between VEGFR-2 and IL-8 gene SNPs and 1-year response to intravitreal ranibizumab for exudative age-related macular degeneration.

MATERIALS & METHODS: Sixty-four eyes underwent a loading phase of three monthly intravitreal injections of ranibizumab 0.5 mg/0.05 ml followed by Pro Re Nata retreatment. VEGFR-2 rs2071559 (-604 A/G) and IL-8 rs4073 (-251 A/T) were analyzed.

RESULTS: Ranibizumab was significantly more effective as measured by visual acuity in patients harboring the IL-8 rs4073 TT genotype (p = 0.045), whereas patients carrying the VEGFR-2 rs2071559 CC genotype revealed better functional response as measured by mean retinal sensitivity (p = 0.034).

CONCLUSION: IL-8 rs4073 and VEGFR-2 rs2071559 genotypes may represent important molecular determinants to modulate final outcomes in neovascular age-related macular degeneration patients.

Original languageEnglish
Pages (from-to)35-39
Number of pages5
JournalPharmacogenomics
Volume17
Issue number1
DOIs
Publication statusPublished - 2016

Keywords

  • age-related macular degeneration
  • IL-8
  • pharmacogenetics
  • ranibizumab
  • SNPs
  • VEGF-2

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Fingerprint Dive into the research topics of 'IL-8 and VEGFR-2 polymorphisms modulate long-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration'. Together they form a unique fingerprint.

Cite this